Microcirculatory  ||| S:0 E:17 ||| JJ
changes  ||| S:17 E:25 ||| NNS
and  ||| S:25 E:29 ||| CC
skeletal  ||| S:29 E:38 ||| JJ
muscle  ||| S:38 E:45 ||| NN
oxygenation  ||| S:45 E:57 ||| VBZ
measured  ||| S:57 E:66 ||| VBN
at  ||| S:66 E:69 ||| IN
rest  ||| S:69 E:74 ||| NN
by  ||| S:74 E:77 ||| IN
non-infrared  ||| S:77 E:90 ||| JJ
spectroscopy  ||| S:90 E:103 ||| NN
in  ||| S:103 E:106 ||| IN
patients  ||| S:106 E:115 ||| NNS
with  ||| S:115 E:120 ||| IN
and  ||| S:120 E:124 ||| CC
without  ||| S:124 E:132 ||| IN
diabetes  ||| S:132 E:141 ||| FW
undergoing  ||| S:141 E:152 ||| FW
haemodialysis  ||| S:152 E:166 ||| FW
Haemodialysis  ||| S:166 E:180 ||| NNP
has  ||| S:180 E:184 ||| VBZ
direct  ||| S:184 E:191 ||| JJ
and  ||| S:191 E:195 ||| CC
indirect  ||| S:195 E:204 ||| JJ
effects  ||| S:204 E:212 ||| NNS
on  ||| S:212 E:215 ||| IN
skin  ||| S:215 E:220 ||| NN
and  ||| S:220 E:224 ||| CC
muscle  ||| S:224 E:231 ||| NN
microcirculatory  ||| S:231 E:248 ||| NN
regulation  ||| S:248 E:259 ||| NN
that  ||| S:259 E:264 ||| WDT
are  ||| S:264 E:268 ||| VBP
severe  ||| S:268 E:275 ||| JJ
enough  ||| S:275 E:282 ||| JJ
to  ||| S:282 E:285 ||| TO
worsen  ||| S:285 E:292 ||| VB
tolerance  ||| S:292 E:302 ||| NN
to  ||| S:302 E:305 ||| TO
physical  ||| S:305 E:314 ||| JJ
exercise  ||| S:314 E:323 ||| NN
and  ||| S:323 E:327 ||| CC
muscle  ||| S:327 E:334 ||| NN
asthenia  ||| S:334 E:343 ||| NN
in  ||| S:343 E:346 ||| IN
patients  ||| S:346 E:355 ||| NNS
undergoing  ||| S:355 E:366 ||| VBG
dialysis ||| S:366 E:374 ||| NN
,  ||| S:374 E:376 ||| ,
thus  ||| S:376 E:381 ||| RB
compromising  ||| S:381 E:394 ||| JJ
patients ||| S:394 E:402 ||| NNS
'  ||| S:402 E:404 ||| POS
quality  ||| S:404 E:412 ||| NN
of  ||| S:412 E:415 ||| IN
life  ||| S:415 E:420 ||| NN
and  ||| S:420 E:424 ||| CC
increasing  ||| S:424 E:435 ||| VBG
the  ||| S:435 E:439 ||| DT
risk  ||| S:439 E:444 ||| NN
of  ||| S:444 E:447 ||| IN
mortality ||| S:447 E:456 ||| NN
.  ||| S:456 E:458 ||| .
In  ||| S:458 E:461 ||| IN
diabetes  ||| S:461 E:470 ||| VBG
these  ||| S:470 E:476 ||| DT
circumstances  ||| S:476 E:490 ||| NNS
are  ||| S:490 E:494 ||| VBP
further  ||| S:494 E:502 ||| RB
complicated ||| S:502 E:513 ||| VBN
,  ||| S:513 E:515 ||| ,
leading  ||| S:515 E:523 ||| VBG
to  ||| S:523 E:526 ||| TO
an  ||| S:526 E:529 ||| DT
approximately  ||| S:529 E:543 ||| RB
sixfold  ||| S:543 E:551 ||| JJ
increase  ||| S:551 E:560 ||| NN
in  ||| S:560 E:563 ||| IN
the  ||| S:563 E:567 ||| DT
incidence  ||| S:567 E:577 ||| NN
of  ||| S:577 E:580 ||| IN
critical  ||| S:580 E:589 ||| JJ
limb  ||| S:589 E:594 ||| NN
ischaemia  ||| S:594 E:604 ||| NNS
and  ||| S:604 E:608 ||| CC
amputation ||| S:608 E:618 ||| NN
.  ||| S:618 E:620 ||| .
Our  ||| S:620 E:624 ||| PRP$
aim  ||| S:624 E:628 ||| NN
in  ||| S:628 E:631 ||| IN
this  ||| S:631 E:636 ||| DT
study  ||| S:636 E:642 ||| NN
was  ||| S:642 E:646 ||| VBD
to  ||| S:646 E:649 ||| TO
investigate  ||| S:649 E:661 ||| VB
in  ||| S:661 E:664 ||| IN
vivo  ||| S:664 E:669 ||| NN
whether  ||| S:669 E:677 ||| IN
haemodialysis  ||| S:677 E:691 ||| NN
induces  ||| S:691 E:699 ||| VBZ
major  ||| S:699 E:705 ||| JJ
changes  ||| S:705 E:713 ||| NNS
in  ||| S:713 E:716 ||| IN
skeletal  ||| S:716 E:725 ||| JJ
muscle  ||| S:725 E:732 ||| NN
oxygenation  ||| S:732 E:744 ||| NNS
and  ||| S:744 E:748 ||| CC
blood  ||| S:748 E:754 ||| NN
flow ||| S:754 E:758 ||| NN
,  ||| S:758 E:760 ||| ,
microvascular  ||| S:760 E:774 ||| JJ
compliance  ||| S:774 E:785 ||| NN
and  ||| S:785 E:789 ||| CC
tissue  ||| S:789 E:796 ||| NN
metabolic  ||| S:796 E:806 ||| NN
rate  ||| S:806 E:811 ||| NN
in  ||| S:811 E:814 ||| IN
patients  ||| S:814 E:823 ||| NNS
with  ||| S:823 E:828 ||| IN
and  ||| S:828 E:832 ||| CC
without  ||| S:832 E:840 ||| IN
diabetes ||| S:840 E:848 ||| NN
.  ||| S:848 E:850 ||| .
The  ||| S:850 E:854 ||| DT
study  ||| S:854 E:860 ||| NN
included  ||| S:860 E:869 ||| VBD
20  ||| S:869 E:872 ||| CD
consecutive  ||| S:872 E:884 ||| JJ
patients  ||| S:884 E:893 ||| NNS
with  ||| S:893 E:898 ||| IN
and  ||| S:898 E:902 ||| CC
without  ||| S:902 E:910 ||| IN
diabetes  ||| S:910 E:919 ||| NN
undergoing  ||| S:919 E:930 ||| VBG
haemodialysis  ||| S:930 E:944 ||| NN
at  ||| S:944 E:947 ||| IN
Sant  ||| S:947 E:952 ||| NNP
Andrea  ||| S:952 E:959 ||| NNP
University  ||| S:959 E:970 ||| NNP
Hospital ||| S:970 E:978 ||| NNP
,  ||| S:978 E:980 ||| ,
Rome  ||| S:980 E:985 ||| NNP
from  ||| S:985 E:990 ||| IN
March  ||| S:990 E:996 ||| NNP
to  ||| S:996 E:999 ||| TO
April  ||| S:999 E:1005 ||| NNP
2007 ||| S:1005 E:1009 ||| CD
.  ||| S:1009 E:1011 ||| .
Near-infrared  ||| S:1011 E:1025 ||| JJ
spectroscopy  ||| S:1025 E:1038 ||| NNS
( ||| S:1038 E:1039 ||| -LRB-
NIRS ||| S:1039 E:1043 ||| NNP
)  ||| S:1043 E:1045 ||| -RRB-
quantitative  ||| S:1045 E:1058 ||| JJ
measurements  ||| S:1058 E:1071 ||| NNS
of  ||| S:1071 E:1074 ||| IN
tissue  ||| S:1074 E:1081 ||| NN
haemoglobin  ||| S:1081 E:1093 ||| NN
concentrations  ||| S:1093 E:1108 ||| NNS
in  ||| S:1108 E:1111 ||| IN
oxygenated  ||| S:1111 E:1122 ||| NNS
[ ||| S:1122 E:1123 ||| -LRB-
HbO2 ||| S:1123 E:1127 ||| NNP
]  ||| S:1127 E:1129 ||| -RRB-
and  ||| S:1129 E:1133 ||| CC
deoxygenated  ||| S:1133 E:1146 ||| JJ
forms  ||| S:1146 E:1152 ||| NNS
[ ||| S:1152 E:1153 ||| -LRB-
HHb ||| S:1153 E:1156 ||| NNP
]  ||| S:1156 E:1158 ||| -RRB-
were  ||| S:1158 E:1163 ||| VBD
obtained  ||| S:1163 E:1172 ||| VBN
in  ||| S:1172 E:1175 ||| IN
the  ||| S:1175 E:1179 ||| DT
calf  ||| S:1179 E:1184 ||| NN
once  ||| S:1184 E:1189 ||| RB
hourly  ||| S:1189 E:1196 ||| JJ
for  ||| S:1196 E:1200 ||| IN
4  ||| S:1200 E:1202 ||| CD
hours  ||| S:1202 E:1208 ||| NNS
during  ||| S:1208 E:1215 ||| IN
dialysis ||| S:1215 E:1223 ||| NN
.  ||| S:1223 E:1225 ||| .
Consecutive  ||| S:1225 E:1237 ||| JJ
venous  ||| S:1237 E:1244 ||| JJ
occlusions  ||| S:1244 E:1255 ||| NN
allowed  ||| S:1255 E:1263 ||| VBD
one  ||| S:1263 E:1267 ||| CD
to  ||| S:1267 E:1270 ||| TO
obtain  ||| S:1270 E:1277 ||| VB
muscular  ||| S:1277 E:1286 ||| JJ
blood  ||| S:1286 E:1292 ||| NN
flow  ||| S:1292 E:1297 ||| NN
( ||| S:1297 E:1298 ||| -LRB-
mBF ||| S:1298 E:1301 ||| NNP
) ||| S:1301 E:1302 ||| -RRB-
,  ||| S:1302 E:1304 ||| ,
microvascular  ||| S:1304 E:1318 ||| JJ
compliance  ||| S:1318 E:1329 ||| NN
and  ||| S:1329 E:1333 ||| CC
muscle  ||| S:1333 E:1340 ||| NN
oxygen  ||| S:1340 E:1347 ||| NN
consumption  ||| S:1347 E:1359 ||| NN
( ||| S:1359 E:1360 ||| -LRB-
mVO2 ||| S:1360 E:1364 ||| NNP
) ||| S:1364 E:1365 ||| -RRB-
.  ||| S:1365 E:1367 ||| .
The  ||| S:1367 E:1371 ||| DT
tissue  ||| S:1371 E:1378 ||| NN
oxygen  ||| S:1378 E:1385 ||| NN
saturation  ||| S:1385 E:1396 ||| NNS
( ||| S:1396 E:1397 ||| -LRB-
StO2 ||| S:1397 E:1401 ||| NNP
)  ||| S:1401 E:1403 ||| -RRB-
and  ||| S:1403 E:1407 ||| CC
content  ||| S:1407 E:1415 ||| NN
( ||| S:1415 E:1416 ||| -LRB-
CtO2 ||| S:1416 E:1420 ||| NNP
)  ||| S:1420 E:1422 ||| -RRB-
as  ||| S:1422 E:1425 ||| IN
well  ||| S:1425 E:1430 ||| RB
as  ||| S:1430 E:1433 ||| IN
the  ||| S:1433 E:1437 ||| DT
microvascular  ||| S:1437 E:1451 ||| JJ
bed  ||| S:1451 E:1455 ||| NN
volume  ||| S:1455 E:1462 ||| NN
were  ||| S:1462 E:1467 ||| VBD
derived  ||| S:1467 E:1475 ||| VBN
from  ||| S:1475 E:1480 ||| IN
the  ||| S:1480 E:1484 ||| DT
haemoglobin  ||| S:1484 E:1496 ||| JJ
concentration ||| S:1496 E:1509 ||| NN
.  ||| S:1509 E:1511 ||| .
Nonparametric  ||| S:1511 E:1525 ||| JJ
tests  ||| S:1525 E:1531 ||| NNS
were  ||| S:1531 E:1536 ||| VBD
used  ||| S:1536 E:1541 ||| VBN
to  ||| S:1541 E:1544 ||| TO
compare  ||| S:1544 E:1552 ||| VB
data  ||| S:1552 E:1557 ||| NNS
within  ||| S:1557 E:1564 ||| IN
each  ||| S:1564 E:1569 ||| DT
group  ||| S:1569 E:1575 ||| NN
and  ||| S:1575 E:1579 ||| CC
among  ||| S:1579 E:1585 ||| IN
the  ||| S:1585 E:1589 ||| DT
groups  ||| S:1589 E:1596 ||| NNS
and  ||| S:1596 E:1600 ||| CC
with  ||| S:1600 E:1605 ||| IN
a  ||| S:1605 E:1607 ||| DT
group  ||| S:1607 E:1613 ||| NN
of  ||| S:1613 E:1616 ||| IN
22  ||| S:1616 E:1619 ||| CD
matched  ||| S:1619 E:1627 ||| VBN
healthy  ||| S:1627 E:1635 ||| JJ
controls ||| S:1635 E:1643 ||| NNS
.  ||| S:1643 E:1645 ||| .
The  ||| S:1645 E:1649 ||| DT
total  ||| S:1649 E:1655 ||| JJ
haemoglobin  ||| S:1655 E:1667 ||| JJ
concentration  ||| S:1667 E:1681 ||| NN
and  ||| S:1681 E:1685 ||| CC
[ ||| S:1685 E:1686 ||| -LRB-
HHb ||| S:1686 E:1689 ||| NNP
]  ||| S:1689 E:1691 ||| -RRB-
increased  ||| S:1691 E:1701 ||| VBD
significantly  ||| S:1701 E:1715 ||| RB
during  ||| S:1715 E:1722 ||| IN
dialysis  ||| S:1722 E:1731 ||| NN
in  ||| S:1731 E:1734 ||| IN
patients  ||| S:1734 E:1743 ||| NNS
without  ||| S:1743 E:1751 ||| IN
and  ||| S:1751 E:1755 ||| CC
with  ||| S:1755 E:1760 ||| IN
diabetes ||| S:1760 E:1768 ||| NN
.  ||| S:1768 E:1770 ||| .
Only  ||| S:1770 E:1775 ||| RB
in  ||| S:1775 E:1778 ||| IN
patients  ||| S:1778 E:1787 ||| NNS
with  ||| S:1787 E:1792 ||| IN
diabetes ||| S:1792 E:1800 ||| NN
,  ||| S:1800 E:1802 ||| ,
dialysis  ||| S:1802 E:1811 ||| NN
involved  ||| S:1811 E:1820 ||| VBD
a  ||| S:1820 E:1822 ||| DT
[ ||| S:1822 E:1823 ||| -LRB-
HbO2 ||| S:1823 E:1827 ||| NNP
] ||| S:1827 E:1828 ||| -RRB-
,  ||| S:1828 E:1830 ||| ,
CtO2  ||| S:1830 E:1835 ||| NNP
and  ||| S:1835 E:1839 ||| CC
increase  ||| S:1839 E:1848 ||| NN
but  ||| S:1848 E:1852 ||| CC
left  ||| S:1852 E:1857 ||| VBD
mVO2  ||| S:1857 E:1862 ||| CD
unchanged ||| S:1862 E:1871 ||| JJ
.  ||| S:1871 E:1873 ||| .
Multiple  ||| S:1873 E:1882 ||| JJ
regression  ||| S:1882 E:1893 ||| NN
StO2  ||| S:1893 E:1898 ||| CD
analysis  ||| S:1898 E:1907 ||| NN
disclosed  ||| S:1907 E:1917 ||| VBD
a  ||| S:1917 E:1919 ||| DT
significant  ||| S:1919 E:1931 ||| JJ
direct  ||| S:1931 E:1938 ||| JJ
correlation  ||| S:1938 E:1950 ||| NN
of  ||| S:1950 E:1953 ||| IN
StO2  ||| S:1953 E:1958 ||| CD
with  ||| S:1958 E:1963 ||| IN
HbO2  ||| S:1963 E:1968 ||| NNP
and  ||| S:1968 E:1972 ||| CC
an  ||| S:1972 E:1975 ||| DT
inverse  ||| S:1975 E:1983 ||| JJ
correlation  ||| S:1983 E:1995 ||| NN
with  ||| S:1995 E:2000 ||| IN
mVO2 ||| S:2000 E:2004 ||| CD
.  ||| S:2004 E:2006 ||| .
Dialysis  ||| S:2006 E:2015 ||| NNP
increased  ||| S:2015 E:2025 ||| VBD
mBF  ||| S:2025 E:2029 ||| JJ
only  ||| S:2029 E:2034 ||| JJ
in  ||| S:2034 E:2037 ||| IN
diabetic  ||| S:2037 E:2046 ||| JJ
patients ||| S:2046 E:2054 ||| NNS
.  ||| S:2054 E:2056 ||| .
Microvascular  ||| S:2056 E:2070 ||| JJ
compliance  ||| S:2070 E:2081 ||| NN
decreased  ||| S:2081 E:2091 ||| VBD
rapidly  ||| S:2091 E:2099 ||| RB
and  ||| S:2099 E:2103 ||| CC
significantly  ||| S:2103 E:2117 ||| RB
during  ||| S:2117 E:2124 ||| IN
the  ||| S:2124 E:2128 ||| DT
first  ||| S:2128 E:2134 ||| JJ
hour  ||| S:2134 E:2139 ||| NN
of  ||| S:2139 E:2142 ||| IN
dialysis  ||| S:2142 E:2151 ||| NN
in  ||| S:2151 E:2154 ||| IN
both  ||| S:2154 E:2159 ||| DT
groups ||| S:2159 E:2165 ||| NNS
.  ||| S:2165 E:2167 ||| .
Our  ||| S:2167 E:2171 ||| PRP$
NIRS  ||| S:2171 E:2176 ||| JJ
findings  ||| S:2176 E:2185 ||| NNS
suggest  ||| S:2185 E:2193 ||| VBP
that  ||| S:2193 E:2198 ||| DT
haemodialysis  ||| S:2198 E:2212 ||| NN
in  ||| S:2212 E:2215 ||| IN
subjects  ||| S:2215 E:2224 ||| NNS
at  ||| S:2224 E:2227 ||| IN
rest  ||| S:2227 E:2232 ||| NN
brings  ||| S:2232 E:2239 ||| VBZ
about  ||| S:2239 E:2245 ||| RB
major  ||| S:2245 E:2251 ||| JJ
changes  ||| S:2251 E:2259 ||| NNS
in  ||| S:2259 E:2262 ||| IN
skeletal  ||| S:2262 E:2271 ||| JJ
muscle  ||| S:2271 E:2278 ||| NN
oxygenation ||| S:2278 E:2289 ||| NN
,  ||| S:2289 E:2291 ||| ,
blood  ||| S:2291 E:2297 ||| NN
flow ||| S:2297 E:2301 ||| NN
,  ||| S:2301 E:2303 ||| ,
microvascular  ||| S:2303 E:2317 ||| JJ
compliance  ||| S:2317 E:2328 ||| NN
and  ||| S:2328 E:2332 ||| CC
tissue  ||| S:2332 E:2339 ||| NN
metabolic  ||| S:2339 E:2349 ||| NN
rate ||| S:2349 E:2353 ||| NN
.  ||| S:2353 E:2355 ||| .
These  ||| S:2355 E:2361 ||| DT
changes  ||| S:2361 E:2369 ||| NNS
differ  ||| S:2369 E:2376 ||| VBP
in  ||| S:2376 E:2379 ||| IN
patients  ||| S:2379 E:2388 ||| NNS
with  ||| S:2388 E:2393 ||| IN
and  ||| S:2393 E:2397 ||| CC
without  ||| S:2397 E:2405 ||| IN
diabetes ||| S:2405 E:2413 ||| NN
.  ||| S:2413 E:2415 ||| .
In  ||| S:2415 E:2418 ||| IN
all  ||| S:2418 E:2422 ||| DT
patients  ||| S:2422 E:2431 ||| NNS
haemodialysis  ||| S:2431 E:2445 ||| VBP
induces  ||| S:2445 E:2453 ||| JJ
changes  ||| S:2453 E:2461 ||| NNS
in  ||| S:2461 E:2464 ||| IN
tissue  ||| S:2464 E:2471 ||| NN
haemoglobin  ||| S:2471 E:2483 ||| NN
concentrations  ||| S:2483 E:2498 ||| NNS
and  ||| S:2498 E:2502 ||| CC
microvascular  ||| S:2502 E:2516 ||| JJ
compliance ||| S:2516 E:2526 ||| NN
,  ||| S:2526 E:2528 ||| ,
whereas  ||| S:2528 E:2536 ||| VBG
in  ||| S:2536 E:2539 ||| IN
patients  ||| S:2539 E:2548 ||| NNS
with  ||| S:2548 E:2553 ||| IN
diabetes  ||| S:2553 E:2562 ||| NN
it  ||| S:2562 E:2565 ||| PRP
alters  ||| S:2565 E:2572 ||| VBP
tissue  ||| S:2572 E:2579 ||| JJ
blood  ||| S:2579 E:2585 ||| NN
flow ||| S:2585 E:2589 ||| NN
,  ||| S:2589 E:2591 ||| ,
tissue  ||| S:2591 E:2598 ||| NN
oxygenation  ||| S:2598 E:2610 ||| NNS
( ||| S:2610 E:2611 ||| -LRB-
CtO2 ||| S:2611 E:2615 ||| NNP
,  ||| S:2615 E:2617 ||| ,
[ ||| S:2617 E:2618 ||| -LRB-
HbO2 ||| S:2618 E:2622 ||| NNP
] ||| S:2622 E:2623 ||| -RRB-
)  ||| S:2623 E:2625 ||| -RRB-
and  ||| S:2625 E:2629 ||| CC
the  ||| S:2629 E:2633 ||| DT
metabolic  ||| S:2633 E:2643 ||| JJ
rate  ||| S:2643 E:2648 ||| NN
( ||| S:2648 E:2649 ||| -LRB-
mVO2 ||| S:2649 E:2653 ||| NNP
) ||| S:2653 E:2654 ||| -RRB-
.  ||| S:2654 E:2656 ||| .
In  ||| S:2656 E:2659 ||| IN
these  ||| S:2659 E:2665 ||| DT
patients  ||| S:2665 E:2674 ||| NNS
the  ||| S:2674 E:2678 ||| DT
mVO2  ||| S:2678 E:2683 ||| NNP
is  ||| S:2683 E:2686 ||| VBZ
correlated  ||| S:2686 E:2697 ||| VBN
to  ||| S:2697 E:2700 ||| TO
the  ||| S:2700 E:2704 ||| DT
blood  ||| S:2704 E:2710 ||| NN
supply ||| S:2710 E:2716 ||| NN
.  ||| S:2716 E:2718 ||| .
The  ||| S:2718 E:2722 ||| DT
effects  ||| S:2722 E:2730 ||| NNS
of  ||| S:2730 E:2733 ||| IN
haemodialysis  ||| S:2733 E:2747 ||| NN
on  ||| S:2747 E:2750 ||| IN
cell  ||| S:2750 E:2755 ||| NN
damage  ||| S:2755 E:2762 ||| NN
remain  ||| S:2762 E:2769 ||| VBP
to  ||| S:2769 E:2772 ||| TO
be  ||| S:2772 E:2775 ||| VB
clarified ||| S:2775 E:2784 ||| VBN
.  ||| S:2784 E:2786 ||| .
The  ||| S:2786 E:2790 ||| DT
absence  ||| S:2790 E:2798 ||| NN
of  ||| S:2798 E:2801 ||| IN
StO2  ||| S:2801 E:2806 ||| CD
changes  ||| S:2806 E:2814 ||| NNS
is  ||| S:2814 E:2817 ||| VBZ
probably  ||| S:2817 E:2826 ||| RB
linked  ||| S:2826 E:2833 ||| VBN
to  ||| S:2833 E:2836 ||| TO
an  ||| S:2836 E:2839 ||| DT
opposite  ||| S:2839 E:2848 ||| NN
[ ||| S:2848 E:2849 ||| -LRB-
HbO2 ||| S:2849 E:2853 ||| NNP
]  ||| S:2853 E:2855 ||| -RRB-
and  ||| S:2855 E:2859 ||| CC
mVO2  ||| S:2859 E:2864 ||| CD
pattern ||| S:2864 E:2871 ||| NN
.  ||| S:2871 E:2873 ||| .
